Table 3. Chemotherapy and outcome.

Case no.		Treatment (see details*)	Response to treatment
1		SIOP MMT 952 protocol	Unable to assess response (microscopic residues), no clinical recurrence after cessation of chemotherapy
2		No chemotherapy	Refractory disease and death
3		SIOP MMT 952 protocol	No response
4	A	SIOP MMT 953 B protocol	Developed pulmonary metastasis during treatment (7 weeks) → rescue chemotherapy (B)
	B	SIOPEL 3 High Risk	Stable disease after 4 cycles of treatment
5	A	SIOP MMT 952 protocol	Progressive disease after 2 courses → rescue chemotherapy (B)
	B	Carboplatin, etoposide	Stable disease after six cycles of treatment

^*SIOP MMT 952 protocol: vincristine 1.5 mg m⁻² (weeks 1, 2, 3, 4, 5, 6, 7, 10, 13, 16, 19, 22 and 25); actinomycin D 1.5 mg m⁻² (weeks 1, 4, 7, 10, 13, 16, 19, 22 and 25); ifosfamide 6 g m⁻² – over 2 days (weeks 1, 4, 7, 10, 13, 16, 19, 22 and 25). ^*SIOP MMT 953 B protocol: vincristine 1.5 mg m⁻² (weeks 1, 2, 3, 4, 5, 6, 7, 10, 13, 16, 19, 22 and 25); actinomycin D 1.5 mg m⁻² (weeks 1, 10 and 19); ifosfamide 9 g m⁻² over 3 days (weeks 1, 7, 10, 16, 19 and 25); carboplatin 500 mg m⁻² (weeks 4, 10 and 22); epirubicin 150 mg m⁻² (weeks 4, 10 and 22); etoposide 150 mg m⁻² over 3 days, (weeks 7, 16 and 25). ^*SIOPEL 3 high risk (protocol for hepatoblastoma): cisplatin 80 mg m⁻² (days 1, 29, 57 and 85); carboplatin 500 mg m⁻² (days 15, 43 and 71); doxorubicin 60 mg m⁻² over 48 h (days 15, 43 and 71). ^*Carboplatin, etoposide: carboplatin 600–800 mg m⁻² per course; etoposide 150 mg m⁻² (days 1, 2 and 3 each course).